Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

BACKGROUND: Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor T-cell based anti-CD19 therapy. The ZUMA-1 study, multicenter, single-arm, registrational Phase 1/2 study of axi-cel demonstrated high objective response rate in patients with relapsed/refractory large B-cell ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Koji, Makita, Shinichi, Goto, Hideki, Kanda, Junya, Fujii, Nobuharu, Shimada, Kazuyuki, Akashi, Koichi, Izutsu, Koji, Teshima, Takanori, Fukuda, Natsuko, Sumitani, Tokuhito, Sumi, Hiroyuki, Shimizu, Shinji, Kakurai, Yasuyuki, Yoshikawa, Kenji, Tobinai, Kensei, Usui, Noriko, Hatake, Kiyohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732921/
https://www.ncbi.nlm.nih.gov/pubmed/34599413
http://dx.doi.org/10.1007/s10147-021-02033-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732921/
https://www.ncbi.nlm.nih.gov/pubmed/34599413
http://dx.doi.org/10.1007/s10147-021-02033-4

Ejemplares similares